Use of incretin-based therapies.
Session:
How do SGLT2 inhibitors and incretin-based therapy exert their effects on cardiovascular disease?
Topic:
Metabolic Syndrome, Insulin, Insulin Resistance
Speaker:
Professor L. Ryden (Stockholm, SE)
Event:
ESC Congress 2018
Congress Presentation
About the speaker
Professor Lars Ryden
Karolinska Institute, Stockholm (Sweden)
37
presentations
1
follower
3 more presentations in this session
Epigenetic signatures and cardiovascular risk in diabetes.
Speaker: Professor F. Cosentino (Stockholm, SE)
Access the full session
How do SGLT2 inhibitors and incretin-based therapy exert their effects on cardiovascular disease?
Speakers:
Professor L. Ryden, Professor F. Cosentino, Professor B. Staels, Professor E. Ferrannini
About the event
ESC 365 is supported by
